Document Detail


Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells.
MedLine Citation:
PMID:  11676393     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Several reports of clinical trials of immunotherapy using dendritic cells have been published to date. In this study, we investigated the safety and clinical response of immunotherapy with fusions of dendritic and glioma cells for the treatment of patients with malignant glioma. Eight patients with malignant glioma, ranging in age from 4 to 63 years old, participated in this study. Dendritic cells were generated from peripheral blood. Cultured autologous glioma cells were established from surgical specimens in each case. Fusion cells of dendritic and glioma cells were prepared with polyethylene glycol, and the fusion efficiency ranged from 9.2 to 35.3% (mean, 21.9%). All patients received the fusion cells every three weeks for a minimum of 3, and a maximum of 7, immunizations. Fusion cells were injected intradermally, close to a cervical lymph node. The percentage of CD16- and CD56-positive cells in peripheral blood lymphocytes slightly increased after immunization in 4 out of 5 cases investigated. Peripheral blood mononuclear cells were incubated with irradiated autologous glioma or U87MG cells and supernatants were harvested. In 6 cases analyzed, the concentration of interferon-gamma in the supernatant increased after immunization. Clinical results showed that there were no serious adverse effects and two partial responses. Although the results of the phase I clinical trial of fusion cells indicated that this treatment safely induced immune responses. we were unable to establish a statistically significant treatment-associated response rate, due to the limited sample population. Therefore, further evaluation of the role of adjuvant cytokines is necessary.
Authors:
T Kikuchi; Y Akasaki; M Irie; S Homma; T Abe; T Ohno
Related Documents :
18591233 - A candida albicans mannoprotein deprived of its mannan moiety is efficiently taken up a...
12816993 - Dendritic cells support sequential reprogramming of chemoattractant receptor profiles d...
19187963 - Comparative analysis of four lipoproteins from mycoplasma mycoides subsp. mycoides smal...
Publication Detail:
Type:  Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Cancer immunology, immunotherapy : CII     Volume:  50     ISSN:  0340-7004     ISO Abbreviation:  Cancer Immunol. Immunother.     Publication Date:  2001 Sep 
Date Detail:
Created Date:  2001-10-24     Completed Date:  2001-11-01     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  8605732     Medline TA:  Cancer Immunol Immunother     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  337-44     Citation Subset:  IM    
Affiliation:
Department of Oncology, The Institute of DNA Medicine, Jikei University, Tokyo, Japan. tkikuchi@jikei.ac.jp
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Cell Fusion*
Child, Preschool
Dendritic Cells / immunology*
Female
Glioma / immunology,  therapy*
Humans
Interferon-gamma / biosynthesis
Male
Middle Aged
T-Lymphocytes / immunology
Vaccination
Chemical
Reg. No./Substance:
82115-62-6/Interferon-gamma

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Myocardial infarction following a bee sting.
Next Document:  ALVAC-mediated gene transfer is efficient in lymphoid malignancies of T-and early B-cell origin, but...